Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) on February 3, 2020, covering the event date of January 31, 2020. The filing addresses the company's compliance status with The Nasdaq Capital Market listing rules.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material change reported is the resolution of a delisting warning. Previously, on October 30, 2019, the Company received notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price requirement for 30 consecutive business days. On January 31, 2020, the Company received written notice that it had regained compliance with Rule 5550(a)(2) because the stock closed above $1.00 for 10 consecutive trading days between January 16 and January 30, 2020. Consequently, Nasdaq has closed the matter.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or new risk factors. The document confirms the removal of the immediate risk of delisting due to low bid price as of the reporting date.
Investor Verification Checklist
- Verify the current trading price of CTXR to ensure continued compliance with the $1.00 minimum bid price rule.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the stock price recovery.
- Monitor future filings for any recurrence of low bid price warnings or other listing standard deficiencies.